Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report

Non‐SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab‐flyo reaches maximum concentration.

Detalles Bibliográficos
Autores principales: Burns, Stephanie, Lewis, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077312/
https://www.ncbi.nlm.nih.gov/pubmed/33936709
http://dx.doi.org/10.1002/ccr3.4060
Descripción
Sumario:Non‐SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab‐flyo reaches maximum concentration.

Ejemplares similares